mchsrosМедико-биологические и социально-психологические проблемы безопасности в чрезвычайных ситуацияхMedicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations1995-44412541-7487«The Nikiforov Russian Center of Emergency and Radiation Medicine»10.25016/2541-7487-2021-0-4-78-84mchsros-710Research ArticleБиологические проблемыBiological IssuesГлиофибриллярный кислый протеин (GFAP) в сыворотке крови у пациентов с травматическим поражением головного мозгаGlial fibrillary acidic protein (GFAP) in blood serum of patients with traumatic brain injuryЛюбимоваН. В.LyubimovaN. V.

Любимова Нина Васильевна – доктор биологических наук профессор, ведущий научный сотрудник

115478, Москва, Каширское шоссе, д.24

Nina V. Lyubimova – Dr. Biol. Sci. Prof., Lead Researcher

24, Kashirskoye Highway, Moscow, 115478

iochimia@yandex.ruТимофеевЮ. С.TimofeevYu. S.

Тимофеев Юрий Сергеевич – кандидат медицинских наук, врач клинической лаборатории диагностики

115478, Москва, Каширское шоссе, д.24

Yurii S. Timofeev, Cand. Med. Sci, Clinical Laboratory Diagnostics Doctor

24, Kashirskoye Highway, Moscow, 115478

Timofeev_lab@mail.ruБекяшевА. Х.BekyashevA. Kh.

Бекяшев Али Хасьянович – доктор медицинских наук, заведующий отделением нейрохирургии

115478, Москва, Каширское шоссе, д.24

Ali Kh. Bekyashev – Dr. Med. Sci., Head of the Department of Neurosurgery

24, Kashirskoye Highway, Moscow, 115478

abekyashev@gmail.comЗыбинаН. Н.ZybinaN. N.

Зыбина Наталья Николаевна – доктор биологических наук профессор, заведующий отделения лаборатории диагностики

Санкт-Петербург, ул. Акад. Лебедева, д.4/2

Natalia N. Zybina – Dr. Biol. Sci., Prof., Head of the Department of Laboratory Diagnostics

4/2, Academic Lebedeva Str., St.-Petersburg, 194044

zybinan@inbox.ruСтилидиИ. С.StilidiI. S.

Стилиди Иван Сократович – доктор медицинских наук профессор, академик РАН, директор

115478, Москва, Каширское шоссе, д.24

Ivan S. Stilidi – Dr Med. Sci Prof., Member of the Russian Academy of Sciences, Director

24, Kashirskoye Highway, Moscow, 115478

ronc@list.ruКушлинскийН. Е.KushlinskiiN. E.

Кушлинский Николай Евгеньевич – доктор медицинских наук профессор, академик РАН, заведующий лаборатории клинической биохимии

115478, Москва, Каширское шоссе, д.24

Nikolay E. Kushlinskii – Dr Med. Sci Prof., Member of the Russian Academy of Sciences, Head of the Laboratory of Clinical Biochemistry

24, Kashirskoye Highway, Moscow, 115478

biochimia@yandex.ruНациональный исследовательский медицинский центр онкологии им. Н.Н. БлохинаРоссияN.N. Blokhin National Medical Research Center of OncologyRussian FederationВсероссийский центр экстренной и радиационной медицины им. А.М. Никифорова МЧС РоссииРоссияNikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of RussiaRussian Federation202119122021047884Copyright © Любимова Н.В., Тимофеев Ю.С., Бекяшев А.Х., Зыбина Н.Н., Стилиди И.С., Кушлинский Н.Е., 20212021Любимова Н.В., Тимофеев Ю.С., Бекяшев А.Х., Зыбина Н.Н., Стилиди И.С., Кушлинский Н.Е.Lyubimova N.V., Timofeev Y.S., Bekyashev A.K., Zybina N.N., Stilidi I.S., Kushlinskii N.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mchsros.elpub.ru/jour/article/view/710Актуальность

Актуальность. Травмы головы в России – самая значительная причина смертности при чрезвычайных ситуациях, дорожно-транспортных происшествиях и инвалидности пострадавших. Нейроспецифические белки, такие как глиофибриллярный кислый белок (GFAP), являются маркерами поражения нервной ткани и нарушения гематоэнцефалического барьера. Анализ GFAP в сыворотке крови у пациентов может стать потенциальным неинвазивным методом оценки степени тяжести и прогноза черепно-мозговой травмы.

Цель – анализ уровней GFAP в сыворотке крови у больных с травматическим поражением центральной нервной системы в различной степени тяжести и ее исхода.

Методология

Методология. Уровни GFAP определяли иммуноферментным методом реактивами «Human GFAP ELISA» («BioVendor», США) в сыворотке крови у 47 пациентов с травматическим поражением головного мозга до начала лечения и у 42 практически здоровых доноров.

Результаты и их анализ

Результаты и их анализ. Частота выявления GFAP в общей группе больных с черепно-мозговой травмой составила 38,3% (18 из 47 пациентов), тогда как в контрольной группе маркер практически не выявлялся. Получены статистически значимые различия в уровнях GFAP в сыворотке крови в зависимости от степени тяжести и исхода черепно-мозговой травмы. Базальная средняя концентрация маркера в сыворотке крови при неблагоприятном исходе черепно-мозговой травмы в 10 раз выше, чем у пациентов с благоприятным исходом.

Заключение

Заключение. GFAP является потенциальным маркером для оценки степени тяжести и прогноза у больных с черепно-мозговой травмой.

Relevance

Relevance. Head injuries in Russia are the most significant cause of death in emergencies and road traffic accidents, as well as disability of victims. Neurospecific proteins such as glial fibrillary acidic protein (GFAP) are markers of neural tissue damage and blood-brain barrier dysfunction. Blood serum GFAP analysis can become a possible noninvasive method to assess brain injury severity and prognosis.

Intention

Intention. To analyze GFAP levels in blood serum of patients having central nervous system traumas of varying severity as well as the injury outcomes.

Methodology

Methodology. GFAP levels were measured in the blood serum of 47 patients with traumatic brain injury before their treatment and in 42 apparently healthy donors using immunoenzyme method (Human GFAP ELISA, BioVendor, USA).

Results and Discussion

Results and Discussion. GFAP detection frequency was 38.3 % (18 out of 47 people) for the group of patients with traumatic brain injury, while the marker was nearly undetectable in the control group. There were statistically significant differences in serum GFAP levels depending on severity and outcome. The basal average marker concentration in the group with poor outcome was 10 times higher than in patients with a favorable outcome.

Conclusion

Conclusion. GFAP is a potential marker to assess severity and prognosis of traumatic brain injur

чрезвычайная ситуациядорожно-транспортный травматизмтравма головного мозгаглиофибриллярный кислый протеинсыворотка кровиemergencybrain injuryroad traffic injuryglial fibrillary acidic protein (GFAP)blood serumReferencesЛюбимова Н.В., Тимофеев Ю.С., Кушлинский Н.Е. Неспецифические белки в сыворотке крови у больных с опухолями головного мозга и неврологическими заболеваниями неопухолевой этиологии // Мед.-биол. и соц.-психол. пробл. безопасности в чрезв. ситуациях. 2016. № 3. С. 90–95. DOI: 10.25016/2541-7487-2016-0-3-90-95.Lyubimova N.V., Timofeev Yu.S., Kushlinskii N.E. Nespetsificheskie belki v syvorotke krovi u bol’nykh s opukholyami golovnogo mozga i nevrologicheskimi zabolevaniyami neopukholevoi etiologii [Neurospesific proteins in the serum of patients with brain tumors and neurological diseases of non-tumor ethiology]. Mediko-biologicheskie i sotsial’no-psikhologicheskie problemy bezopasnosti v chrezvychaynykh situatsiyakh. [Medicо-Biological and Socio-Psychological Problems of Safety in Emergency Situations]. 2016. N 3. Pp. 90–95. DOI: 10.25016/2541-7487-2016-0-3-90-95. (In Russ.)Ковтун Н.А., Савельева М.И., Трофименко А.В. [и др.]. Диагностическое и прогностическое значение определения белков – маркеров повреждения мозга при легких черепно-мозговых травмах // Лабораторная служба. 2021. № 2. С. 28–33. DOI: 10.17116/labs20211002128.Kovtun N.A., Savelyeva M.I., Trophimenko A.V. [et al.]. Diagnosticheskoe i prognosticheskoe znachenie opredeleniya belkov – markerov povrezhdeniya mozga pri legkikh cherepno-mozgovykh travmakh [Diagnostic and prognostic value of protein markers determination of brain damage in mild traumatic brain injuries]. Laboratornaya sluzhba [Laboratory Service]. 2021. N 2. Pp. 28–33. DOI: 10.17116/labs20211002128. (In Russ.)Baumgarten P., Quick-Weller J., Gessler F. [et al.]. Pre- and early postoperative GFAP serum levels in glioma and brain metastases // J. Neurooncol. 2018. Vol. 139, N 3. P. 541–546. DOI: 10.1007/s11060-018-2898-1.Baumgarten P., Quick-Weller J., Gessler F. [et al.]. Pre- and early postoperative GFAP serum levels in glioma and brain metastases. J. Neurooncol. 2018. Vol. 139, N 3. Pp. 541–546. DOI: 10.1007/s11060-018-2898-1.Bazarian J.J., Biberthaler P., Welch R.D. [et al.]. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study // Lancet Neurol. 2018. Vol. 17, N 9. P. 782–789. DOI: 10.1016/S1474-4422(18)30231-X.Bazarian J.J., Biberthaler P., Welch R.D. [et al.]. Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study. Lancet Neurol. 2018. Vol. 17, N 9. Pp. 782–789. DOI: 10.1016/S1474-4422(18)30231-X.Brommeland T., Rosengren L., Fridlund S. [et al.]. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas // Acta Neurol. Scand. 2007. Vol. 116, N 6. P. 380–384. DOI: 10.1111/j.1600-0404.2007.00889.x.Brommeland T., Rosengren L., Fridlund S. [et al.]. Serum levels of glial fibrillary acidic protein correlate to tumour volume of high-grade gliomas. Acta Neurol. Scand. 2007. Vol. 116, N 6. Pp. 380–384. DOI: 10.1111/j.1600-0404.2007.00889.x.Foerch C., Niessner M., Back T. [et al.]. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke // Clin. Chem. 2012. Vol. 58, N 1. P. 237–245. DOI:10.1373/clinchem.2011.172676.Foerch C., Niessner M., Back T. [et al.]. Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin. Chem. 2012. Vol. 58, N 1. Pp. 237–245. DOI:10.1373/clinchem.2011.172676.Gállego Pérez-Larraya J., Paris S., Idbaih A. [et al.]. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma // Cancer. 2014. Vol. 120, N 24. P. 3972–3980. DOI: 10.1002/cncr.28949.Gállego Pérez-Larraya J., Paris S., Idbaih A. [et al.]. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma. Cancer. 2014. Vol. 120, N 24. Pp. 3972–3980. DOI: 10.1002/cncr.28949.Hiskens M.I., Schneiders A.G., Angoa-Pérez M. [et al.]. Blood biomarkers for assessment of mild traumatic brain injury and chronic traumatic encephalopathy // Biomarkers. 2020. Vol. 25, N 3. P. 213–227. DOI: 10.1080/1354750X.2020.1735521.Hiskens M.I., Schneiders A.G., Angoa-Pérez M. [et al.]. Blood biomarkers for assessment of mild traumatic brain injury and chronic traumatic encephalopathy. Biomarkers. 2020. Vol. 25, N 3. Pp. 213–227. DOI: 10.1080/1354750X.2020.1735521.Kiviniemi A., Gardberg M., Frantzén J. [et al.]. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival // J. Neurooncol. 2015. Vol. 124, N 2. P. 237–245. DOI: 10.1007/s11060-015-1829-7.Kiviniemi A., Gardberg M., Frantzén J. [et al.]. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival. J. Neurooncol. 2015. Vol. 124, N 2. Pp. 237–245. DOI: 10.1007/s11060-015-1829-7.Lewis L.M., Papa L., Bazarian J.J. [et al.]. Biomarkers may predict unfavorable neurological outcome after mild traumatic brain Injury // J. Neurotrauma. 2020. Vol. 37, N 24. P. 2624–2631. DOI: 10.1089/neu.2020.7071.Lewis L.M., Papa L., Bazarian J.J. [et al.]. Biomarkers may predict unfavorable neurological outcome after mild traumatic brain Injury. J. Neurotrauma. 2020. Vol. 37, N 24. Pp. 2624–2631. DOI: 10.1089/neu.2020.7071.Lumpkins K.M., Bochicchio G.V., Keledjian K. [et al.]. Glial fibrillary acidic protein is highly correlated with brain injury // J. Trauma. 2008. Vol. 65, N 4. P. 778–782. Discussion 782–784. DOI: 10.1097/TA.0b013e318185db2d.Lumpkins K.M., Bochicchio G.V., Keledjian K. [et al.]. Glial fibrillary acidic protein is highly correlated with brain injury. J. Trauma. 2008. Vol. 65, N 4. P. 778–782. Discussion 782–784. DOI: 10.1097/TA.0b013e318185db2d.Lyubimova N.V., Timofeev Y.S., Mitrofanov A.A. [et al.]. Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors // Bull. Exp. Biol. Med. 2020. Vol. 168, N 4. P. 503–506. DOI: 10.1007/s10517-020-04741-9.Lyubimova N.V., Timofeev Y.S., Mitrofanov A.A. [et al.]. Glial Fibrillary Acidic Protein in the Diagnosis and Prognosis of Malignant Glial Tumors. Bull. Exp. Biol. Med. 2020. Vol. 168, N 4. Pp. 503–506. DOI: 10.1007/s10517-020-04741-9.Mayer C.A., Brunkhorst R., Niessner M. [et al.]. Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases // PLoS One. 2013. Vol. 8, N 4. P. e62101. DOI: 10.1371/journal.pone.0062101.Mayer C.A., Brunkhorst R., Niessner M. [et al.]. Blood levels of glial fibrillary acidic protein (GFAP) in patients with neurological diseases. PLoS One. 2013. Vol. 8, N 4. P. e62101. DOI: 10.1371/journal.pone.0062101.Papa L., Brophy G.M., Welch R.D. [et al.]. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury // JAMA Neurol. 2016. Vol. 73, N 5. P. 551–560. DOI: 10.1001/jamaneurol.2016.0039.Papa L., Brophy G.M., Welch R.D. [et al.]. Time course and diagnostic accuracy of glial and neuronal blood biomarkers GFAP and UCH-L1 in a large cohort of trauma patients with and without mild traumatic brain injury. JAMA Neurol. 2016. Vol. 73, N 5. Pp. 551–560. DOI: 10.1001/jamaneurol.2016.0039.Pelinka L.E., Kroepfl A., Leixnering M., Buchinger W. [et al]. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome // J. Neurotrauma. 2004. Vol. 21, N 11. P. 1553–1561. DOI: 10.1089/neu.2004.21.1553.Pelinka L.E., Kroepfl A., Leixnering M., Buchinger W. [et al]. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J. Neurotrauma. 2004. Vol. 21, N 11. Pp. 1553–1561. DOI: 10.1089/neu.2004.21.1553.Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease // Brain Res. 2015. Vol. 1600. P. 17–31. DOI: 10.1016/j.brainres.2014.12.027.Petzold A. Glial fibrillary acidic protein is a body fluid biomarker for glial pathology in human disease. Brain Res. 2015. Vol. 1600. Pp. 17–31. DOI: 10.1016/j.brainres.2014.12.027.Seidenfaden S.C., Kjerulff J.L., Juul N. [et al.]. Diagnostic accuracy of prehospital serum S100B and GFAP in patients with mild traumatic brain injury: a prospective observational multicenter cohort study – “the PreTBI I study” // Scand. J. Trauma Resusc. Emerg. Med. 2021. Vol. 29, N 1. P. 75. DOI: 10.1186/s13049-02100891-5.Seidenfaden S.C., Kjerulff J.L., Juul N. [et al.]. Diagnostic accuracy of prehospital serum S100B and GFAP in patients with mild traumatic brain injury: a prospective observational multicenter cohort study – “the PreTBI I study”. Scand. J. Trauma Resusc. Emerg. Med. 2021. Vol. 29, N 1. Pp. 75. DOI: 10.1186/s13049-021-00891-5.Takala R.S., Posti J.P., Runtti H. [et al.]. Glial Fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 as outcome predictors in traumatic brain injury // World Neurosurg. 2016. Vol. 87. P. 8–20. DOI: 10.1016/j.wneu.2015.10.066.Takala R.S., Posti J.P., Runtti H. [et al.]. Glial Fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 as outcome predictors in traumatic brain injury. World Neurosurg. 2016. Vol. 87. Pp. 8–20. DOI: 10.1016/j.wneu.2015.10.066.Tichy J., Spechtmeyer S., Mittelbronn M. [et al.]. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma // J. Neurooncol. 2016. Vol. 126, N 2. P. 361–369. DOI: 10.1007/s11060-015-1978-8.Tichy J., Spechtmeyer S., Mittelbronn M. [et al.]. Prospective evaluation of serum glial fibrillary acidic protein (GFAP) as a diagnostic marker for glioblastoma. J. Neurooncol. 2016. Vol. 126, N 2. Pp. 361–369. DOI: 10.1007/s11060-015-1978-8.Vos P.E., Jacobs B., Andriessen T.M. [et al.]. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study // Neurology. 2010. Vol. 75, N 20. P. 1786–1793. DOI: 10.1212/WNL.0b013e3181fd62d2.Vos P.E., Jacobs B., Andriessen T.M. [et al.]. GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology. 2010. Vol. 75, N 20. Pp. 1786–1793. DOI: 10.1212/WNL.0b013e3181fd62d2.Welch R.D., Ayaz S.I., Lewis L.M. [et al.]. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury // J. Neurotrauma. 2016. Vol. 33, N 2. P. 203–214. DOI: 10.1089/neu.2015.4149.Welch R.D., Ayaz S.I., Lewis L.M. [et al.]. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury. J. Neurotrauma. 2016. Vol. 33, N 2. Pp. 203–214. DOI: 10.1089/neu.2015.4149.

The authors declare that there are no conflicts of interest present.